Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.
Harker
L A
LA
Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Hanson
S R
SR
Kelly
A B
AB
D000595:Amino Acid Sequence; D000818:Animals; D000991:Antithrombins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001792:Blood Platelets / Q000502:physiology; D006470:Hemorrhage / Q000139:chemically induced*; D024764:Hirudin Therapy; D006629:Hirudins / Q000009:adverse effects / Q000031:analogs & derivatives; D006801:Humans; D008969:Molecular Sequence Data; D010215:Papio; D010446:Peptide Fragments / Q000009:adverse effects / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors / Q000502:physiology; D011323:Primates; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013917:Thrombin / Q000502:physiology; D013927:Thrombosis / Q000188:drug therapy*
D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011994:Recombinant Proteins; D013917:Thrombin; C074619:bivalirudin